GFP
SAGE

Gryphon Financial Partners’s Sage Therapeutics SAGE Stock Holding History

Gryphon Financial Partners’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-1,135
Closed -$181K – 171
2019
Q1 		$181K Buy
+1,135
New +$164K 0.05% 120
2018
Q3 		– Sell
-366
Closed -$57K – 696
2018
Q2 		$57K Buy
+366
New +$57.5K 0.03% 207

Other funds holding SAGE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Gryphon Financial Partners's SAGE Position: Q2 2019 in Review

Gryphon Financial Partners sold out of Sage Therapeutics (SAGE) in Q2 2019, closing a stake of 1,135 shares — an estimated $181K sold.

Gryphon Financial Partners first reported a position in SAGE in Q2 2018 and held it in 2 quarters. The position peaked at $181K in Q1 2019. 272 funds tracked by Wall St. Rank hold SAGE as of Q2 2019.

  • Gryphon Financial Partners reported no remaining Sage Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Gryphon Financial Partners sold 1,135 Sage Therapeutics shares in Q2 2019, an estimated $181K.
  • Gryphon Financial Partners first reported a position in Sage Therapeutics in Q2 2018 and held it in 2 quarters.
  • Gryphon Financial Partners's Sage Therapeutics position peaked at $181K in Q1 2019.
  • 272 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2019.

Based on Gryphon Financial Partners's 13F filing for Q2 2019, filed 9 Aug 2019.